Sun Pharma shares in spotlight after Q2 profit rises 28% YoY to Rs 3,040 crore. Should you invest?
Sun Pharma shares will be in the spotlight on Tuesday after the company reported 28% year-on-year (YoY) growth in its consolidated net profit at Rs 3,040 crore in the second quarter. The same stood at Rs 2,375 crore in the last year quarter.
Revenue from operations in the reporting period rose 9% YoY to Rs 13,291 crore.
EBITDA for the quarter stood at Rs 3,939 crore, showing a growth of 24% YoY, with a resulting EBITDA margin of 29.6%. Formulation sales in India jumped 11% YoY to Rs 4,265 crore, accounting for about 32% of total consolidated sales. For the first half, sales were Rs 8,410 crore.
US formulation sales during the second quarter grew 20% YoY to $517 million and accounted for 33% of total sales. The emerging markets sales came in at $293 million for the September quarter, growing by 3% YoY.
Formulation sales in Rest of World (ROW) markets, meanwhile dropped 3% YoY to $199 million in Q2FY25. For API, external sales rose 7% YoY to Rs 534 crore in the reporting second quarter.
Stock Trading
Options Scalping Made Easy
By — Sivakumar Jayachandran, Ace Scalper
Stock Trading
Stock Investing Made Easy: Beginner's Stock Market Investment Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
ROC Made Easy: Master Course for ROC Stock Indicator
By — Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading
A2Z of Stock Market for Beginners: Stock Market Course For Beginners
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Heikin Ashi Trading Tactics: Master the Art of
